共 161 条
[1]
Won KA(2020)Triple-negative breast cancer therapy: Current and future perspectives (Review) International Journal of Oncology 57 1245-1261
[2]
Spruck C(2021)Immunotherapy in triple-negative breast cancer Cancer Journal 27 59-66
[3]
Emens LA(2021)Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Annals of Oncology 32 994-100
[4]
Miles D(2022)Current clinical trial landscape of OX40 agonists Current Oncology Reports 24 951-960
[5]
Gligorov J(2022)Prognostic and clinicopathologic associations of LAG-3 expression in triple-negative breast cancer Applied Immunohistochemistry & Molecular Morphology 30 62-71
[6]
André F(2021)Leveraging epigenetics to enhance the efficacy of immunotherapy Clinical Epigenetics 13 115-1016
[7]
Cameron D(2019)Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Journal for Immunotherapy of Cancer 7 29-E9648
[8]
Schneeweiss A(2021)Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells Journal for Immunotherapy of Cancer 9 e001197-1339
[9]
Barrios C(2018)A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment Cancer Research 78 1003-undefined
[10]
Xu B(2018)Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment Proceedings of the National Academy of Sciences of the United States of America 115 E9640-undefined